FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367296073> ?p ?o ?g. }

• W4367296073 abstract "<h3>Objective:</h3> Our goal is to increase the clinical awareness and improve the treatment of immune checkpoint inhibitor-induced CNS Vasculitis. <h3>Background:</h3> Over the last few years, immune checkpoint inhibitors have been increasingly utilized to treat solid malignant tumors and associated metastatic disease. However, there has also been a higher incidence of observed immune mediated adverse events, such as vasculitis of the central and peripheral nervous system. <h3>Design/Methods:</h3> N/A <h3>Results:</h3> A 27-year-old woman with triple negative breast cancer was started on neoadjuvant therapy with paclitaxel, carboplatin, and pembrolizumab followed by bilateral mastectomy in March 2022. She was then placed on adjuvant and maintenance therapy with pembrolizumab. A month later, the patient developed new onset left facial palsy and left arm weakness. She was found to have a right MCA subocclusive thrombus and multifocal right M2 and ICA narrowing with acute on subacute infarcts of the right MCA territory. No evidence of metastatic disease was noted. Prescribed Apixaban for presumed hyper coagulability of malignancy. Three months later, she underwent 5-day course of IV immunoglobulin and was started on prednisone after she developed worsening left arm weakness and numbness with evolving acute on subacute right MCA infarcts. Vessel wall imaging showed enhancement of multiple large and medium intracranial vessels. Diagnostic cerebral angiogram confirmed CNS vasculitis. CSF analysis showed glucose 64, protein 17, 1 WBC, Immunoglobulin G index 0.5 and no oligoclonal bands. CSF infectious studies, rheumatologic evaluation, autoimmune encephalitis and paraneoplastic panels were all negative. Despite treatment, the patient required 5-day course of methylprednisolone 1g daily and was given induction therapy with Cyclophosphamide a month later. <h3>Conclusions:</h3> Immune checkpoint Inhibitor-induced CNS Vasculitis is rare but likely underdiagnosed. As these therapies have been increasingly utilized, we have observed more immune mediated vascular and non-vascular adverse events. Having a high clinical suspicion can promote early aggressive treatment and hopefully improved outcomes. <b>Disclosure:</b> Dr. Simons has nothing to disclose. Dr. Moreno Gomez has nothing to disclose. Dr. Gordon-Perue has nothing to disclose. Dr. Asdaghi has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Heart Association." @default.
• W4367296073 created "2023-04-29" @default.
• W4367296073 creator A5025040396 @default.
• W4367296073 creator A5031716353 @default.
• W4367296073 creator A5036692682 @default.
• W4367296073 creator A5055858701 @default.
• W4367296073 date "2023-04-25" @default.
• W4367296073 modified "2023-09-26" @default.
• W4367296073 title "Pembrolizumab-Induced CNS Vasculitis: A Likely Underdiagnosed Cause of Primary Angiitis of the CNS (P4-5.030)" @default.
• W4367296073 doi "https://doi.org/10.1212/wnl.0000000000204253" @default.
• W4367296073 hasPublicationYear "2023" @default.
• W4367296073 type Work @default.
• W4367296073 citedByCount "1" @default.
• W4367296073 countsByYear W43672960732023 @default.
• W4367296073 crossrefType "proceedings-article" @default.
• W4367296073 hasAuthorship W4367296073A5025040396 @default.
• W4367296073 hasAuthorship W4367296073A5031716353 @default.
• W4367296073 hasAuthorship W4367296073A5036692682 @default.
• W4367296073 hasAuthorship W4367296073A5055858701 @default.
• W4367296073 hasConcept C121608353 @default.
• W4367296073 hasConcept C126322002 @default.
• W4367296073 hasConcept C141071460 @default.
• W4367296073 hasConcept C2776015282 @default.
• W4367296073 hasConcept C2777701055 @default.
• W4367296073 hasConcept C2779134260 @default.
• W4367296073 hasConcept C2780057760 @default.
• W4367296073 hasConcept C71924100 @default.
• W4367296073 hasConcept C90924648 @default.
• W4367296073 hasConceptScore W4367296073C121608353 @default.
• W4367296073 hasConceptScore W4367296073C126322002 @default.
• W4367296073 hasConceptScore W4367296073C141071460 @default.
• W4367296073 hasConceptScore W4367296073C2776015282 @default.
• W4367296073 hasConceptScore W4367296073C2777701055 @default.
• W4367296073 hasConceptScore W4367296073C2779134260 @default.
• W4367296073 hasConceptScore W4367296073C2780057760 @default.
• W4367296073 hasConceptScore W4367296073C71924100 @default.
• W4367296073 hasConceptScore W4367296073C90924648 @default.
• W4367296073 hasLocation W43672960731 @default.
• W4367296073 hasOpenAccess W4367296073 @default.
• W4367296073 hasPrimaryLocation W43672960731 @default.
• W4367296073 hasRelatedWork W2002120878 @default.
• W4367296073 hasRelatedWork W2003938723 @default.
• W4367296073 hasRelatedWork W2047967234 @default.
• W4367296073 hasRelatedWork W2118496982 @default.
• W4367296073 hasRelatedWork W2364998975 @default.
• W4367296073 hasRelatedWork W2369162477 @default.
• W4367296073 hasRelatedWork W2439875401 @default.
• W4367296073 hasRelatedWork W4238867864 @default.
• W4367296073 hasRelatedWork W2519357708 @default.
• W4367296073 hasRelatedWork W2525756941 @default.
• W4367296073 isParatext "false" @default.
• W4367296073 isRetracted "false" @default.
• W4367296073 workType "article" @default.